{"doi":"10.1002/acn3.51738","title":"Baseline characteristics of the North American prodromal Synucleinopathy cohort","abstract":"OBJECTIVE: Rapid eye movement (REM) sleep behavior disorder (RBD) is widely considered a prodromal synucleinopathy, as most with RBD develop overt synucleinopathy within ~10 years. Accordingly, RBD offers an opportunity to test potential treatments at the earliest stages of synucleinopathy. The North American Prodromal Synucleinopathy (NAPS) Consortium has created a multisite RBD participant, primarily clinic-based cohort to better understand characteristics at diagnosis, and in future work, identify predictors of phenoconversion, develop synucleinopathy biomarkers, and enable early stage clinical trial enrollment. METHODS: Participants ≥18 years of age with overnight polysomnogram-confirmed RBD without Parkinson's disease, dementia, multiple system atrophy, or narcolepsy were enrolled from nine sites across North America (8/2018 to 4/2021). Data collection included family/personal history of RBD and standardized assessments of cognitive, motor, sensory, and autonomic function. RESULTS: Outcomes are primarily reported based on sex (361 total: n = 295 male, n = 66 female), and secondarily based on history of antidepressant use (n = 200 with, n = 154 without; with correction for sex differences) and based on extent of synucleinopathy burden (n = 56 defined as isolated RBD, n = 305 defined as RBD+ [i.e., exhibiting ≥1 abnormality]). Overall, these participants commonly demonstrated abnormalities in global cognition (MoCA; 38%), motor function (alternate tap test; 48%), sensory (BSIT; 57%), autonomic function (orthostatic hypotension, 38.8%), and anxiety/depression (BAI and PHQ-9; 39.3% and 31%, respectively). INTERPRETATION: These RBD participants, assessed with extensive history, demographic, cognitive, motor, sensory, and autonomic function demonstrated a lack of sex differences and high frequency of concomitant neurological abnormalities. These participants will be valuable for future longitudinal study and neuroprotective clinical trials.","journal":"Annals of Clinical and Translational Neurology","year":2023,"id":320526,"datarank":1.109407827394665,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"self_citation_contribution":0.5837730447165941,"citation_network_contribution":0.525634782678071,"self_endowment_contribution":0.5837730447165941,"citer_contribution":0.525634782678071,"corpus_percentile":81.65854413243599,"corpus_rank":2372,"citation_count":48,"citer_count":26,"citers_with_citation_signal":18,"citers_with_endowment":18,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.7525,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":432079,"name":"Miranda M. Lim","orcid":"0000-0003-3876-3196","position":1,"is_corresponding":false},{"id":897051,"name":"Allison Keil","orcid":"0000-0002-6569-0618","position":2,"is_corresponding":false},{"id":108592,"name":"Ronald B. Postuma","orcid":"0000-0002-6468-4734","position":3,"is_corresponding":false},{"id":630708,"name":"Amélie Pelletier","orcid":"0009-0001-5930-9796","position":4,"is_corresponding":false},{"id":746117,"name":"Jean‐François Gagnon","orcid":"0000-0003-1132-0563","position":5,"is_corresponding":false},{"id":428950,"name":"Erik K. St. Louis","orcid":"0000-0002-2833-8826","position":6,"is_corresponding":false},{"id":253905,"name":"Leah K. Forsberg","orcid":"0000-0003-4086-9598","position":7,"is_corresponding":false},{"id":253904,"name":"Julie A. Fields","orcid":"0000-0002-1282-9866","position":8,"is_corresponding":false},{"id":401430,"name":"Daniel E. Huddleston","orcid":"0000-0003-0503-3736","position":9,"is_corresponding":false},{"id":324171,"name":"Donald L. Bliwise","orcid":"0000-0002-5079-035X","position":10,"is_corresponding":false},{"id":1031229,"name":"Alon Y. Avidan","orcid":"0000-0002-8817-6590","position":11,"is_corresponding":false},{"id":490230,"name":"Michael J. Howell","orcid":"0000-0001-7535-0724","position":12,"is_corresponding":false},{"id":284807,"name":"Carlos H. Schenck","orcid":"0000-0002-0095-2680","position":13,"is_corresponding":false},{"id":379003,"name":"Jennifer McLeland","orcid":"0009-0004-2195-0264","position":14,"is_corresponding":false},{"id":465244,"name":"Susan R. Criswell","orcid":"0000-0001-8467-371X","position":15,"is_corresponding":false},{"id":284800,"name":"Aleksandar Videnović","orcid":"0000-0002-9237-1516","position":16,"is_corresponding":false},{"id":678874,"name":"Emmanuel During","orcid":"0000-0002-0539-5115","position":17,"is_corresponding":false},{"id":619242,"name":"Mitchell G. Miglis","orcid":"0000-0001-8488-0313","position":18,"is_corresponding":false},{"id":438276,"name":"David Shprecher","orcid":"0000-0002-4217-0097","position":19,"is_corresponding":false},{"id":681834,"name":"Joyce Lee‐Iannotti","orcid":"0000-0003-2710-3133","position":20,"is_corresponding":false},{"id":108587,"name":"Bradley F. Boeve","orcid":"0000-0002-4153-8187","position":21,"is_corresponding":false},{"id":284801,"name":"Yo‐El S. Ju","orcid":"0000-0001-9397-7475","position":22,"is_corresponding":false},{"id":897050,"name":"Jonathan E. Elliott","orcid":"0000-0002-6992-6851","position":0,"is_corresponding":true}],"reference_count":59,"raw_metadata":null,"created_at":"2026-07-19T01:07:22.377587Z","pmid":"36751940","pmcid":"PMC10109527","fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}